{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:06:31Z","timestamp":1756512391546,"version":"3.44.0"},"reference-count":65,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780323998734"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/b978-0-323-99873-4.00017-7","type":"book-chapter","created":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T07:58:46Z","timestamp":1685347126000},"page":"345-360","source":"Crossref","is-referenced-by-count":0,"title":["Targeting DNA damage response pathways in glioblastoma: From mechanistic insights to advances in the clinic"],"prefix":"10.1016","author":[{"given":"Mariana","family":"Pereira","sequence":"first","affiliation":[]},{"given":"B\u00e1rbara","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Nuno","family":"Vale","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/B978-0-323-99873-4.00017-7_bb0010","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1146\/annurev.biochem.73.011303.073723","article-title":"Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints","volume":"73","author":"Sancar","year":"2004","journal-title":"Annu Rev Biochem"},{"issue":"7120","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0015","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature05236","article-title":"Glioma stem cells promote radioresistance by preferential activation of the DNA damage response","volume":"444","author":"Bao","year":"2006","journal-title":"Nature"},{"issue":"17","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0020","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1001\/jama.2013.280319","article-title":"Glioblastoma and other malignant gliomas: a clinical review","volume":"310","author":"Omuro","year":"2013","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0025","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a012583","article-title":"Base excision repair","volume":"5","author":"Krokan","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"23","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0030","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.3390\/ijms20236092","article-title":"DNA oxidation and excision repair pathways","volume":"20","author":"Lee","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0035","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a012609","article-title":"Nucleotide excision repair in eukaryotes","volume":"5","author":"Sch\u00e4rer","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1\u20132","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0300-483X(03)00287-7","article-title":"Mechanisms of human DNA repair: an update","volume":"193","author":"Christmann","year":"2003","journal-title":"Toxicology"},{"issue":"7267","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0045","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08467","article-title":"The DNA-damage response in human biology and disease","volume":"461","author":"Jackson","year":"2009","journal-title":"Nature"},{"issue":"5","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0050","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/PPO.0000000000000540","article-title":"DNA damage response in glioblastoma: mechanism for treatment resistance and emerging therapeutic strategies","volume":"27","author":"Bonm","year":"2021","journal-title":"Cancer J"},{"issue":"3","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0055","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3390\/biomedicines7030069","article-title":"Temozolomide and other alkylating agents in glioblastoma therapy","volume":"7","author":"Strobel","year":"2019","journal-title":"Biomedicines"},{"issue":"10","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0060","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2176\/nmc.ra.2018-0141","article-title":"Potential strategies overcoming the temozolomide resistance for glioblastoma","volume":"58","author":"Jiapaer","year":"2018","journal-title":"Neurol Med Chir (Tokyo)"},{"issue":"11","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0065","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1200\/JCO.1998.16.11.3570","article-title":"Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma","volume":"16","author":"Friedman","year":"1998","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0070","first-page":"2402","article-title":"O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair","volume":"59","author":"Spiro","year":"1999","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0075","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s10147-014-0769-0","article-title":"A phase III study of radiation therapy (RT) and O6-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001","volume":"20","author":"Blumenthal","year":"2015","journal-title":"Int J Clin Oncol"},{"issue":"Suppl. 15","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0080","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1200\/JCO.2019.37.15_suppl.2062","article-title":"A phase I study of MGMT-P140K transfected hematopoetic progenitor cells (HPC) combined with TMZ\/O6BG dose escalation for newly diagnosed, MGMT unmethylated glioblastoma: Tolerance and evidence of survival benefit","volume":"37","author":"Sloan","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0085","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/1535-7163.MCT-14-0810","article-title":"MGMT expression predicts PARP-mediated resistance to temozolomide","volume":"14","author":"Erice","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0090","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/neuonc\/noab003","article-title":"PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma","volume":"23","author":"Wu","year":"2021","journal-title":"Neuro Oncol"},{"issue":"7381","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0095","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nature10760","article-title":"The DNA damage response and cancer therapy","volume":"481","author":"Lord","year":"2012","journal-title":"Nature"},{"issue":"14","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0100","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.3390\/ijms21144910","article-title":"Targeting the DNA damage response to overcome cancer drug resistance in glioblastoma","volume":"21","author":"Ferri","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0105","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1158\/1535-7163.MCT-17-0975","article-title":"Orally bioavailable and blood-brain barrier-penetrating ATM inhibitor (AZ32) radiosensitizes intracranial gliomas in mice","volume":"17","author":"Karlin","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0110","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/neuonc\/noaa238","article-title":"Brain exposure of the ATM inhibitor AZD1390 in humans-a positron emission tomography study","volume":"23","author":"Jucaite","year":"2021","journal-title":"Neuro Oncol"},{"issue":"22","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0115","doi-asserted-by":"crossref","first-page":"9889","DOI":"10.1021\/acs.jmedchem.8b01187","article-title":"Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agent","volume":"61","author":"Foote","year":"2018","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0120","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13014-018-1020-3","article-title":"ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration","volume":"13","author":"Fr\u00f2sina","year":"2018","journal-title":"Radiat Oncol"},{"issue":"Suppl. 15","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0125","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2020.38.15_suppl.3503","article-title":"Results from a phase I, open-label study of ceralasertib (AZD6738), a novel DNA damage repair agent, in combination with weekly paclitaxel in refractory cancer (NCT02630199)","volume":"38","author":"Lee","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0130","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-human trial of the oral ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0135","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nchembio.573","article-title":"Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR","volume":"7","author":"Reaper","year":"2011","journal-title":"Nat Chem Biol"},{"issue":"3","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0140","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1124\/jpet.121.000845","article-title":"Brain distribution of berzosertib: an ataxia telangiectasia and Rad3-related protein inhibitor for the treatment of glioblastoma","volume":"379","author":"Talele","year":"2021","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0145","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/s13046-019-1434-2","article-title":"The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment","volume":"38","author":"Patties","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0150","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1158\/1078-0432.CCR-14-2588","article-title":"The efficacy of the wee1 inhibitor MK-1775 combined with temozolomide is limited by heterogeneous distribution across the blood-brain barrier in glioblastoma","volume":"21","author":"Pokorny","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0155","doi-asserted-by":"crossref","first-page":"3820","DOI":"10.1158\/1078-0432.CCR-17-3348","article-title":"Phase 0 trial of AZD1775 in first-recurrence glioblastoma patients","volume":"24","author":"Sanai","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"600","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0160","doi-asserted-by":"crossref","first-page":"eabc7275","DOI":"10.1126\/scitranslmed.abc7275","article-title":"Inhibiting DNA-PK induces glioma stem cell differentiation and sensitizes glioblastoma to radiation in mice","volume":"13","author":"Fang","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/B978-0-323-99873-4.00017-7_bb0165","doi-asserted-by":"crossref","first-page":"10463","DOI":"10.2147\/CMAR.S208720","article-title":"First-in-human phase I study of a dual mTOR kinase and DNA-PK inhibitor (CC-115) in advanced malignancy","volume":"11","author":"Munster","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/B978-0-323-99873-4.00017-7_bb0170","doi-asserted-by":"crossref","unstructured":"Van Triest B., Damstrup L., Falkenius J., Budach V., Troost E., Samuels M., et al. A phase Ia\/Ib trial of the DNA-PK inhibitor M3814 in combination with radiotherapy (RT) in patients (pts) with advanced solid tumors: dose-escalation results. J Clin Oncol 2018;36(15_suppl):2518-.","DOI":"10.1200\/JCO.2018.36.15_suppl.2518"},{"issue":"12","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0175","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/1541-7786.MCR-19-0362","article-title":"Therapeutic implications of p53 status on cancer cell fate following exposure to ionizing radiation and the DNA-PK inhibitor M3814","volume":"17","author":"Sun","year":"2019","journal-title":"Mol Cancer Res"},{"key":"10.1016\/B978-0-323-99873-4.00017-7_bb0180","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","article-title":"The senescence-associated secretory phenotype: the dark side of tumor suppression","volume":"5","author":"Copp\u00e9","year":"2010","journal-title":"Annu Rev Pathol"},{"issue":"20","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0185","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1021\/jm8001263","article-title":"4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1","volume":"51","author":"Menear","year":"2008","journal-title":"J Med Chem"},{"issue":"12","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0190","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1093\/neuonc\/noaa104","article-title":"Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial","volume":"22","author":"Hanna","year":"2020","journal-title":"Neuro Oncol"},{"key":"10.1016\/B978-0-323-99873-4.00017-7_bb0195","first-page":"12","article-title":"PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status","volume":"8","author":"Fulton","year":"2017","journal-title":"Clin Transl Radiat Oncol"},{"issue":"Suppl. 15","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0200","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/jco.2014.32.15_suppl.2092","article-title":"A phase I study of niraparib in combination with temozolomide (TMZ) in patients with advanced cancer","volume":"32","author":"Kurzrock","year":"2014","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0205","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.neo.2020.06.009","article-title":"Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor","volume":"22","author":"Xiong","year":"2020","journal-title":"Neoplasia"},{"issue":"362","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0210","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf9246","article-title":"Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action","volume":"8","author":"Pommier","year":"2016","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0215","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28073","article-title":"Phase 1\/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory\/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411)","volume":"67","author":"Schafer","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"6330","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0220","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science (New York, NY)"},{"key":"10.1016\/B978-0-323-99873-4.00017-7_bb0225","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12885-015-1205-1","article-title":"BRCA1 germline mutation and glioblastoma development: report of cases","volume":"15","author":"Boukerroucha","year":"2015","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0230","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3390\/biom11081188","article-title":"BRCAness as a biomarker of susceptibility to PARP inhibitors in glioblastoma multiforme","volume":"11","author":"Xavier","year":"2021","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0235","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2217\/fon.11.2","article-title":"Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer","volume":"7","author":"Thurn","year":"2011","journal-title":"Future Oncol"},{"issue":"1","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0240","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13046-020-01643-6","article-title":"The application of histone deacetylases inhibitors in glioblastoma","volume":"39","author":"Chen","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"issue":"12","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0245","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2008.19.0694","article-title":"Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study","volume":"27","author":"Galanis","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0250","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/neuonc\/nox161","article-title":"Phase I\/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874\/ABTC 02","volume":"20","author":"Galanis","year":"2018","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0255","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/neuonc\/nor198","article-title":"Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study","volume":"14","author":"Friday","year":"2012","journal-title":"Neuro Oncol"},{"issue":"5","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0260","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.ijrobp.2015.04.038","article-title":"A phase 2 study of concurrent radiation therapy, temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma","volume":"92","author":"Krauze","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/B978-0-323-99873-4.00017-7_bb0265","article-title":"A novel hydroxamic acid-based curcumin derivative as potent histone deacetylase inhibitor for the treatment of glioblastoma","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0270","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41419-021-04182-w","article-title":"Histone deacetylase 6 acts upstream of DNA damage response activation to support the survival of glioblastoma cells","volume":"12","author":"Yang","year":"2021","journal-title":"Cell Death Dis"},{"issue":"5","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0275","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.dnarep.2010.01.016","article-title":"The importance of XRCC2 in RAD51-related DNA damage repair","volume":"9","author":"Tambini","year":"2010","journal-title":"DNA Repair"},{"issue":"10","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0280","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1021\/acs.jnatprod.0c00580","article-title":"Cedrol, a sesquiterpene alcohol, enhances the anticancer efficacy of temozolomide in attenuating drug resistance via regulation of the DNA damage response and MGMT expression","volume":"83","author":"Chang","year":"2020","journal-title":"J Nat Prod"},{"issue":"10","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0285","first-page":"3741","article-title":"p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor","volume":"29","author":"Bocangel","year":"2009","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0290","doi-asserted-by":"crossref","first-page":"48","DOI":"10.59566\/IJBS.2017.13048","article-title":"Molecular mechanisms and biological functions of siRNA","volume":"13","author":"Dana","year":"2017","journal-title":"Int J Biomed Sci"},{"issue":"4","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0295","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/nat.2019.0784","article-title":"Formulation of biocompatible targeted ECO\/siRNA nanoparticles with long-term stability for clinical translation of RNAi","volume":"29","author":"Ayat","year":"2019","journal-title":"Nucleic Acid Ther"},{"issue":"11","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0300","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.3390\/cancers12113260","article-title":"Improving radiation response in glioblastoma using ECO\/siRNA nanoparticles targeting DNA damage repair","volume":"12","author":"Lee","year":"2020","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0305","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.3390\/biom5042589","article-title":"Hsp90: a new player in DNA repair?","volume":"5","author":"Pennisi","year":"2015","journal-title":"Biomolecules"},{"issue":"307","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0310","doi-asserted-by":"crossref","first-page":"612354","DOI":"10.3389\/fonc.2021.612354","article-title":"Inhibition of HSP90 as a strategy to radiosensitize glioblastoma: targeting the DNA damage response and beyond","volume":"11","author":"Orth","year":"2021","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0315","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1248\/bpb.b20-00654","article-title":"Involvement of CD73 and A2B receptor in radiation-induced DNA damage response and cell migration in human glioblastoma A172 cells","volume":"44","author":"Kitabatake","year":"2021","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0320","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1038\/s41598-019-40327-w","article-title":"CHD4 regulates the DNA damage response and RAD51 expression in glioblastoma","volume":"9","author":"McKenzie","year":"2019","journal-title":"Sci Rep"},{"issue":"15","key":"10.1016\/B978-0-323-99873-4.00017-7_bb0325","doi-asserted-by":"crossref","first-page":"20140","DOI":"10.18632\/oncotarget.7917","article-title":"Survival kinase genes present prognostic significance in glioblastoma","volume":"7","author":"Varghese","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/B978-0-323-99873-4.00017-7_bb0330","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.683038","article-title":"VRK1 depletion facilitates the synthetic lethality of temozolomide and olaparib in glioblastoma cells","volume":"9","author":"Navarro-Carrasco","year":"2021","journal-title":"Front Cell Dev Biol"}],"container-title":["New Insights Into Glioblastoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323998734000177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:B9780323998734000177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T16:41:41Z","timestamp":1756485701000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780323998734000177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9780323998734"],"references-count":65,"URL":"https:\/\/doi.org\/10.1016\/b978-0-323-99873-4.00017-7","relation":{},"subject":[],"published":{"date-parts":[[2023]]}}}